Single-stranded HDR templates with truncated Cas12a-binding sequences improve knock-in efficiencies in primary human T cells
CRISPR-Cas12a gene editing offers an alternative to Cas9-based methods, providing better targeting of AT-rich regions, simplified guide RNA manufacturing, and high specificity. However, the efficacy of donor-based editing is subject to various factors, with template format playing a crucial role. Currently, the predominant non-viral template format for homology-directed repair (HDR) after nuclease-induced DNA breaks is double-stranded DNA, which is toxic when transfected at high doses. Others have demonstrated that using single-stranded DNA (ssDNA) with flanking double-stranded Cas-target-sequences (CTS) as a template for Cas9-mediated gene editing can mitigate this toxicity and increase knock-in efficiency. Here, we investigate CTS design for AsCas12a Ultra by exploring PAM orientation and binding requirements. Additionally, we rule out ssDNase activity of AsCas12a under cell-physiological Mg<sup>2+</sup> conditions. Finally, we showcase the advantage of ssDNA donors with CTS (ssCTS) at high doses for delivering clinically relevant transgenes of varying sizes into three TCR-CD3 complex genes (<i>TRAC</i>, <i>CD3ζ, CD3ε</i>), achieving up to 90% knock-in rates for a 0.8kb-insert at the <i>CD3ε</i> locus. Long-read sequencing confirmed higher HDR rates and revealed that CTS reduced partial integration events compared to unmodified ssDNA. Overall, AsCas12a and ssCTS represent a platform for highly efficient knock-in in primary human T cells with minimal toxicity.
Authors
- Dimitrios L. Wagner (ORCID: https://orcid.org/0000-0002-2189-3579)
- Robert Greensmith (ORCID: https://orcid.org/0000-0001-8142-0127)
- Eric J. Aird (ORCID: https://orcid.org/0000-0002-4873-042X)
- Grégoire Cullot (ORCID: https://orcid.org/0000-0003-3925-705X)
- Ana-Maria Nitulescu (ORCID: https://orcid.org/0009-0008-0714-6607)
- Maik Stein (ORCID: https://orcid.org/0000-0001-6181-2385)
- Rasmus Otkjær Bak (ORCID: https://orcid.org/0000-0002-7383-0297)
- Nanna S. Mikkelsen (ORCID: https://orcid.org/0000-0002-9061-5345)
- Michael M. Kaminski (ORCID: https://orcid.org/0000-0003-0429-7027)
- Viktor Glaser (ORCID: https://orcid.org/0000-0002-1385-5249)
- Jonas Kath (ORCID: https://orcid.org/0000-0001-7721-7978)
- Weijie Du (ORCID: https://orcid.org/0000-0001-5924-8631)
- Jacob E. Corn (ORCID: https://orcid.org/0000-0002-7798-5309)
Institutions
- Baylor College of Medicine (US)
- Aarhus University (DK)
- Max Delbrück Center (DE)
- ETH Zurich (CH)
- Humboldt-Universität zu Berlin (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1016/j.omtn.2025.102568
- Citations
- 5
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- National Science Foundation
- University of Chicago
- Lotte und Adolf Hotz-Sprenger Stiftung
- European Commission
- Deutsche Forschungsgemeinschaft
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Charité – Universitätsmedizin Berlin
- NOMIS Stiftung
- Berlin Institute of Health
- Horizon 2020 Framework Programme
- HORIZON EUROPE Framework Programme
- European Research Council
- H2020 European Research Council